# A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects

> **NCT05459285** · PHASE1 · COMPLETED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 68 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **BIOLOGICAL:** 14028 injection
- **BIOLOGICAL:** dulaglutide injection

## Key facts

- **NCT ID:** NCT05459285
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-31
- **Primary completion:** 2022-07-02
- **Final completion:** 2022-07-08
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2022-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05459285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05459285, "A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05459285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*